Trial Profile
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Amgen
- 09 Jul 2021 According to a BeiGene media release, the China National Medical Products Administration (NMPA) has conditionally approved KYPROLIS (carfilzomib) for injection in combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma who have received at least two prior therapies, based on data from this trial.
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 12 Sep 2019 According to an Amgen media release, data from this trial will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019.